Hsbc Holdings PLC bought a new position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 833,455 shares of the company’s stock, valued at approximately $10,743,000.
A number of other institutional investors have also modified their holdings of the business. Rhumbline Advisers raised its position in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after purchasing an additional 9,548 shares during the last quarter. American Century Companies Inc. grew its position in Eyepoint Pharmaceuticals by 57.8% during the 2nd quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock worth $636,000 after purchasing an additional 24,752 shares during the last quarter. Invesco Ltd. increased its stake in Eyepoint Pharmaceuticals by 199.8% in the second quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock valued at $1,212,000 after purchasing an additional 85,824 shares during the period. Raymond James Financial Inc. increased its stake in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after buying an additional 600,000 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages have recently weighed in on EYPT. Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Chardan Capital upped their price objective on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Cantor Fitzgerald initiated coverage on Eyepoint Pharmaceuticals in a research report on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price objective for the company. Finally, Guggenheim reissued a “buy” rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.75.
Eyepoint Pharmaceuticals Stock Performance
EYPT stock opened at $12.66 on Thursday. The stock has a market capitalization of $1.06 billion, a PE ratio of -3.62 and a beta of 1.73. The company has a fifty day moving average of $13.21 and a 200-day moving average of $14.10. Eyepoint Pharmaceuticals, Inc. has a one year low of $9.40 and a one year high of $19.11.
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%. Equities analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.31 earnings per share for the current fiscal year.
About Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Stories
- Five stocks we like better than Eyepoint Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report).
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
